Connect Biopharma Holdings

NMQ:CNTB · KYG235491019

BiotechnologySmall

360

Value36

Profit price43

Cash yield1

Sales & asset price54

Price/Sales74

EV / Gross Profit6

Price/Book83

Quality39

Returns on capital19

Return on Capital26

Cash Return on Capital11

Return on Equity21

Profit margins37

Cash backing49

Accruals90

Owner Earnings Margin7

Growth56

Sales growth100

Profit growth80

Reinvestment29

Price momentum22

Safety58

Debt load72

Debt serviceability7

Refinancing13

Debt Payback1

Liquidity86

Sentiment67

Analyst ratings100

Expectations trend92

Opinion Changes98

Price Target Upside86

Market mood26

Value Creation0/20not creating value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Connect Biopharma Holdings doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGM

Founded2015

Employees36

Websiteconnectbiopharm.com

ISINKYG235491019

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

InflammationDermatologyPulmonologyRespiratoryChronic DiseasesBiotechnologyClinical TrialsHealth CareMedicalTherapeutics

Description

Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company. The company is dedicated to transforming care for asthma and chronic obstructive pulmonary disease (‘COPD’). The company is advancing rademikibart, a next-gen…

Analysis

Middle-of-the-road

Connect Biopharma Holdings Limited is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is adequate. The company scores 0/20 on our value-creation score: not creating value. Analysts lean positive.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Jun 2026

All-time low

Mar 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Connect Biopharma Holdings with its peers

Apogee Therapeutics

NMQ:APGE

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Gain Therapeutics

NMQ:GANX

CountryUSA

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

Kodiak Sciences

NMQ:KOD

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Spero Therapeutics

NSQ:SPRO

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Disc Medicine

NMQ:IRON

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Mineralys Therapeutics

NSQ:MLYS

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →